Revvity | PKI - Current Assets


Revvity reported $2.13B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Agilent USD 4.76B 148M Mar/2026
Align Technology USD 2.66B 38.87M Mar/2026
Bio Techne USD 688.05M 50.62M Mar/2026
Bio-Rad Laboratories USD 2.94B 35.9M Mar/2026
Bruker USD 2.1B 108.9M Mar/2026
Celltrion KRW 481.57B 10.97B Mar/2026
Charles River Laboratories USD 1.49B 41.76M Mar/2026
Cspc Pharmaceutical CNY 22.25B 359.48M Dec/2025
Danaher USD 13.94B 1.18B Mar/2026
Dentsply International USD 1.85B 178M Mar/2026
Deva Holding AS TRY 9.13B 1.61B Sep/2023
Dianthus Therapeutics USD 1.12B 710.47M Mar/2026
Divis Laboratories Ltd INR 110.96B 12.53B Mar/2026
Edwards Lifesciences USD 6.23B 510.2M Mar/2026
Illumina USD 2.74B 551M Mar/2026
Intuitive Surgical USD 11.52B 881.5M Mar/2026
IQVIA Holdings USD 6.22B 29M Mar/2026
Kangmei Pharma CNY 6.8B 225.83M Mar/2026
Knight Therapeutics CAD 394.84M 5.86M Dec/2025
Laboratorios Farma EUR 509.33M 128.63M Dec/2023
Laboratory Of America USD 4.56B 538.3M Mar/2026
Malin Corporation EUR 62.6M 26.7M Dec/2024
Medical Developments International AUD 33.75M 1.79M Dec/2025
Mesa Laboratories USD 105.63M 8.2M Dec/2025
Mettler Toledo International USD 1.33B 30.76M Mar/2026
Myriad Genetics USD 312.8M 19.8M Mar/2026
Neuren Pharmaceuticals AUD 332.23M 11.98M Dec/2025
OraSure Technologies USD 240.78M 21.13M Mar/2026
Organigram Holdings CAD 250.09M 6.46M Mar/2026
Ovoca Bio EUR 1.56M 3.39M Jun/2025
Pacific Biosciences Of California USD 369.52M 5.54M Mar/2026
Pharma Mar EUR 273.45M 9.96M Mar/2026
Qiagen NV USD 2B 535.87M Dec/2025
Quest Diagnostics USD 2.57B 188M Mar/2026
Quidel USD 1.38B 70.3M Mar/2026
Repligen USD 1.16B 23.98M Mar/2026
Revvity USD 2.13B 111.43M Mar/2026
Sartorius EUR 1.92B 157.2M Mar/2026
Sino Biopharmaceutical CNY 33.82B 9.13B Jun/2025
Thermo Fisher Scientific USD 22.32B 6.39B Mar/2026
Tilray USD 729.32M 28.18M Sep/2025
Waters USD 3.72B 1.73B Mar/2026
Zealand Pharma A/S 15.67B 950.94M Dec/2025
Zz Pientze Pharmaceu CNY 11.43B 728.95M Mar/2026